## ILMN: Illumina, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.62 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Consistent execution (3/4 quarters beat estimates). Caution: declining volume (51% of avg), momentum weakening (-2.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($120.80)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Illumina (ILMN): Assessing Valuation After a Quiet Share Price Rebound**
- Source: Yahoo Finance | 20251205T181000 | Neutral | Relevance: 100%
- Illumina (ILMN) has seen a recent share price rebound, with a 5.33% gain over 30 days and 30.35% over 90 days, despite a negative 8.6% return over the past year. Analysts generally view the stock as slightly overvalued at $128.96 against a fair value of $119.84, while a Discounted Cash Flow (DCF) model suggests it could be undervalued at $156.27. The primary debate revolves around whether the current price anticipates future growth or if the stock is undervalued given its cash flow trajectory.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.09M) |
| Sells | 11 ($80.42M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Capital World Invest: 13.1% (+20.0%)
- Blackrock Inc.: 12.2% (-3.5%)
- Vanguard Group Inc: 9.6% (-3.5%)
- State Street Corpora: 3.9% (+6.8%)
- Sessa Capital IM, L.: 3.1% (-0.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $80M sold (11 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 25.7x stretched relative to 6% growth. Quality metrics strong (ROE 31%, margin 16%). Insider selling cluster ($80.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.7B |
| Beta | 1.44 |
| 52W Range | $68.70 - $153.06 |
| Short Interest | 7.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 25.7 |
| Current P/E | 27.4 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.5% to 1.2% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.8pp (needs >4.0% for momentum thesis). MRS_5 (-0.0%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.5% shows strong absolute momentum above own 20MA. Outperforming sector by 3.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). Volume at 51% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.16% (CS: 63) | Neutral |
| RSI_14 | 65.8 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 1.035x | Above |
| vs SMA50 | 1.168x | Above |
| vs SMA200 | 1.361x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $128.96
- **Stop Loss:** $120.80 (6.3% risk)
- **Target:** $145.28 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 61
- **Position Value:** $7,866.56
- **Portfolio %:** 7.87%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-05 (Est: $1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.34 | +14.7% |
| 2025Q2 | $1.01 | $1.19 | +17.7% |
| 2025Q1 | $0.94 | $0.97 | +3.3% |
| 2024Q4 | $0.92 | $0.86 | -6.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*